Detralex® 36's 500 mg film-coated tablets
- $42.90
Out Of Stock
Sku:
82ac9d05cdec
Brand:
Servier (France)
The instruction for medical use
of DETRALEX medicine
the Trade name
Detralex
the International unlicensed name
Is not present
the Dosage form
of the Tablet, film coated
Structure
One tablet contains
active agents: the cleaned micronized flavonoidny fraction consisting of diosmin of 90% - 450 mg and flavonoids in the form of hesperidin of 10% - 50 mg,
excipients: gelatin, magnesium stearate, cellulose microcrystalline, starch sodium glycollate, talc, glitserol, macrogoal 6000, methylhydroxypropyl cellulose, gland (III) oxide red E172, sodium lauryl sulfate, titan E171 dioxide, gland (III) oxide yellow E172
Description
of the Tablet of an oval form, film coated salmoncolored color
Pharmacotherapeutic group
Vasoprotectives. The drugs reducing permeability of capillaries. Bioflavonoids. Diosmin in a combination with other
drugs ATX C05CA53 Code Pharmacological Pharmacokinetics In Properties an organism drug biotransformirutsya to phenolic acids.
Detralex is removed from an organism generally through intestines. Kidneys remove 14% of the accepted dose. Elimination half-life (T1/2) makes 11 h.
The pharmacodynamics
Detralex has venotoniziruyushchy and angioprotektorny effect. Reduces extensibility of veins, raises their tone and reduces venous stagnation, reduces permeability of capillaries and increases their resistance, improves microcirculation, improves a lymphatic drainage.
At systematic use of Detralex the reduction of expressiveness of clinical symptoms of chronic venous insufficiency of the lower extremities of the organic and functional nature and also a hemorrhoidal disease is noted.
Indications
symptomatic treatment of venous and lymphatic insufficiency (weight in legs, pain, hypostases and spasms)
the functional symptoms connected with bad attacks of hemorrhoids.
A route of administration and doses
the Recommended dose makes 2 tablets a day, 1 tablet in the middle of the day and 1 tablet in the evening during meal.
At a bad attack of hemorrhoids: 6 tablets a day in the first 4 days (on 2 tablets 3 times a day), then on 4 tablets in the next 3 days (on 2 tablets 2 times a day).
Duration of a course of treatment is defined by the attending physician.
The average duration of treatment is 23 months.
Side effects
Often
diarrhea, dyspepsia, nausea, vomiting
Infrequently
colitis
Seldom
dizziness, a headache, a general malaise
skin rash, an itching, a small tortoiseshell
Frequency is not established
an abdominal pain
edema of face, lips, a century and a Quincke's edema
Contraindications
hypersensitivity to drug
the lactation period
Medicinal interactions
there Are
no Special instructions
At bad attacks of hemorrhoids the use of Detralex does not replace specific treatment of other diseases of anorectal area. Drug is appointed a short course. At inefficiency of the carried-out treatment it is necessary to perform additional examination and to correct therapy. When prescribing drug the patients with disturbances of venous blood circulation should inform them on need of protection from long stay in the sun, long standing standing, decrease in body weight and wearing the special stockings improving blood circulation.
Pregnancy
In pilot studies of teratogenic effect it is not revealed.
So far about any side effects at use of drug for pregnant women it was not reported.
Features of influence on ability to run the vehicle and potentially dangerous mechanisms
Detralex does not affect ability to run motor transport and potentially dangerous mechanisms.
Overdose
of the Message about cases of overdose are absent.
Symptoms: strengthening of side effects
Treatment: symptomatic
the Form of release and packing
On 12 (for packing No. 36) or 15 (for packings No. 30 and No. 60) tablets place in blister strip packaging from a film of polivinilkhloridy and aluminum foil.
On 2 or 4 (for packings No. 30 and No. 60 respectively), or on 3 (for packing No. 36) blister strip packagings together with the instruction for medical use in the state and Russian languages place in a box of cardboard.
To Store storage conditions at a temperature not over 30C.
To store out of children's reach!
A period of storage
4 years
not to use drug after the expiration date specified on packing.
Prescription status
Without prescription
Les Laboratoires Servier Industrie Producer (Le Laboratoir of Servye Indastri), France
the Owner of the registration certificate
of Les Laboratoires Servier (Le Laboratoir of Servye), France
of DETRALEX medicine
the Trade name
Detralex
the International unlicensed name
Is not present
the Dosage form
of the Tablet, film coated
Structure
One tablet contains
active agents: the cleaned micronized flavonoidny fraction consisting of diosmin of 90% - 450 mg and flavonoids in the form of hesperidin of 10% - 50 mg,
excipients: gelatin, magnesium stearate, cellulose microcrystalline, starch sodium glycollate, talc, glitserol, macrogoal 6000, methylhydroxypropyl cellulose, gland (III) oxide red E172, sodium lauryl sulfate, titan E171 dioxide, gland (III) oxide yellow E172
Description
of the Tablet of an oval form, film coated salmoncolored color
Pharmacotherapeutic group
Vasoprotectives. The drugs reducing permeability of capillaries. Bioflavonoids. Diosmin in a combination with other
drugs ATX C05CA53 Code Pharmacological Pharmacokinetics In Properties an organism drug biotransformirutsya to phenolic acids.
Detralex is removed from an organism generally through intestines. Kidneys remove 14% of the accepted dose. Elimination half-life (T1/2) makes 11 h.
The pharmacodynamics
Detralex has venotoniziruyushchy and angioprotektorny effect. Reduces extensibility of veins, raises their tone and reduces venous stagnation, reduces permeability of capillaries and increases their resistance, improves microcirculation, improves a lymphatic drainage.
At systematic use of Detralex the reduction of expressiveness of clinical symptoms of chronic venous insufficiency of the lower extremities of the organic and functional nature and also a hemorrhoidal disease is noted.
Indications
symptomatic treatment of venous and lymphatic insufficiency (weight in legs, pain, hypostases and spasms)
the functional symptoms connected with bad attacks of hemorrhoids.
A route of administration and doses
the Recommended dose makes 2 tablets a day, 1 tablet in the middle of the day and 1 tablet in the evening during meal.
At a bad attack of hemorrhoids: 6 tablets a day in the first 4 days (on 2 tablets 3 times a day), then on 4 tablets in the next 3 days (on 2 tablets 2 times a day).
Duration of a course of treatment is defined by the attending physician.
The average duration of treatment is 23 months.
Side effects
Often
diarrhea, dyspepsia, nausea, vomiting
Infrequently
colitis
Seldom
dizziness, a headache, a general malaise
skin rash, an itching, a small tortoiseshell
Frequency is not established
an abdominal pain
edema of face, lips, a century and a Quincke's edema
Contraindications
hypersensitivity to drug
the lactation period
Medicinal interactions
there Are
no Special instructions
At bad attacks of hemorrhoids the use of Detralex does not replace specific treatment of other diseases of anorectal area. Drug is appointed a short course. At inefficiency of the carried-out treatment it is necessary to perform additional examination and to correct therapy. When prescribing drug the patients with disturbances of venous blood circulation should inform them on need of protection from long stay in the sun, long standing standing, decrease in body weight and wearing the special stockings improving blood circulation.
Pregnancy
In pilot studies of teratogenic effect it is not revealed.
So far about any side effects at use of drug for pregnant women it was not reported.
Features of influence on ability to run the vehicle and potentially dangerous mechanisms
Detralex does not affect ability to run motor transport and potentially dangerous mechanisms.
Overdose
of the Message about cases of overdose are absent.
Symptoms: strengthening of side effects
Treatment: symptomatic
the Form of release and packing
On 12 (for packing No. 36) or 15 (for packings No. 30 and No. 60) tablets place in blister strip packaging from a film of polivinilkhloridy and aluminum foil.
On 2 or 4 (for packings No. 30 and No. 60 respectively), or on 3 (for packing No. 36) blister strip packagings together with the instruction for medical use in the state and Russian languages place in a box of cardboard.
To Store storage conditions at a temperature not over 30C.
To store out of children's reach!
A period of storage
4 years
not to use drug after the expiration date specified on packing.
Prescription status
Without prescription
Les Laboratoires Servier Industrie Producer (Le Laboratoir of Servye Indastri), France
the Owner of the registration certificate
of Les Laboratoires Servier (Le Laboratoir of Servye), France
Related Products
